China NMPA Drug Inspection - Bozhou Yuanguang Traditional Chinese Medicine Pieces Factory

On January 26, 2021, the Gansu Provincial Drug Administration published a quality announcement identifying four batches of substandard drugs from four companies, including the Bozhou Yuanguang Traditional Chinese Medicine Pieces Factory. The findings were based on testing conducted by the Lanzhou Municipal Food and Drug Inspection Institute and other relevant institutions. The primary violation cited was the failure of these drug batches to meet mandatory quality standards. Under the regulatory framework of the National Medical Products Administration (NMPA), authorities have taken immediate control measures, including sealing and seizing the non-compliant products. Formal investigations have been launched against the responsible units, with the results slated for public disclosure within three months. To ensure public safety, the Gansu Provincial Drug Administration has mandated that local market supervision bureaus increase oversight. The involved companies are required to investigate the root causes of the quality issues, formulate comprehensive rectification plans, and implement these measures to eliminate potential health risks. This enforcement action highlights the ongoing commitment of Chinese regulatory bodies to maintaining pharmaceutical integrity and protecting consumer health through rigorous quality surveillance.